All In Biotech

Free tool

FAERS Monitor: Bavencio

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761078 or its brand name (Bavencio, Avelumab). Reports on generic versions are filed under their own applications.

Reports

4,102

Serious

3,741

91% of reports

Hospitalization

1,807

Death reported

946

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • disease progression386
  • death377
  • off label use239
  • diarrhoea171
  • pyrexia150
  • infusion related reaction148
  • fatigue136
  • neoplasm progression125
  • dyspnoea111
  • nausea110
  • chills107
  • hypertension107
  • interstitial lung disease106
  • rash102
  • acute kidney injury89

Reports by year received

View as table
YearReports
201613
2017216
2018389
2019433
2020446
2021565
2022577
2023489
2024438
2025320
2026216

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,057 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neoplasm progressionSignal12518.515.62,048
disease progressionSignal38616.815.35,725
infusion related reactionSignal14811.59.81,406
interstitial lung diseaseSignal10611.29.3980
chillsSignal1074.73.9308
acute kidney injurySignal893.02.4116
hypertensionSignal1072.62.1104
deathSignal3772.22.0270
pyrexiaSignal1502.21.9101
off label use2391.41.228
diarrhoea1711.41.216
rash1021.21.03
dyspnoea1111.00.80
fatigue1360.90.82
nausea1100.70.613

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.